Pharmacokinetics of a high dose of amikacin administered at extended intervals to neonatal foals

American Journal of Veterinary Research

Volumn 65, Issue 4, 2004, Pages 473-479

  Magdesian, K Gary ^a   Wilson, W David ^a   Mihalyi, Judy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIGLYDE V; AMIKACIN; HEPARIN; PENICILLIN G;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BIRTH; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HORSE; KIDNEY FUNCTION; MALE; MATURATION; MEAN RESIDENCE TIME; NEWBORN; NONHUMAN; PHLEBITIS; SEPSIS;

AGE FACTORS; AMIKACIN; ANALYSIS OF VARIANCE; ANIMALS; HORSES; TIME FACTORS;

ANIMALIA; EQUUS CABALLUS;

EID: 1842431800     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.473     Document Type: Article

References (40)

1. Cohen ND. Causes of and farm management factors associated with disease and death in foals. J Am Vet Med Assoc 1994; 204:1644-1651.
2. Marsh PS, Palmer JE. Bacterial isolates from blood and their susceptibility patterns in critically ill foals: 543 cases (1991-1998). J Am Vet Med Assoc 2001;218:1608-1610.
3. Wilson WD, Madigan JE. Comparison of bacteriologic culture of blood and necropsy specimens for determining the cause of foal septicemia: 47 cases (1978-1987). J Am Vet Med Assoc 1989; 195:1759-1763.
4. Owens RC Jr, Banevicius MA, Nicolau DP. In vitro synergistic activities of tobramycin and selected β-lactams against 75 gram-negative clinical isolates. Antimicrob Agents Chemother 1997; 41:2586-2588.
5. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986;80:126-137.
6. Klastersky J, Hensgens C, Meunier-Carpentier F. Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: Double-blind clinical trial. J Infect Dis 1976;134(suppl):S433-S440.
7. Chadwick EG, Shulman ST, Yogev R. Correlation of antibiotic synergy in vitro and in vivo: Use of an animal model of neutropenic gram-negative sepsis. J Infect Dis 1986;154:670-675.
8. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99.
9. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-448.
10. Kapusnik JE, Hackbath CJ, Chambers HF, et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988; 158:7-12.
11. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: Increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3:38-44.
12. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996;312:338-345.
13. Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002;28:936-942.
14. McClure JT, Rosin E. Comparison of amikacin dosing regimens in neutropenic guinea pigs with Escherichia coli infection. Am J Vet Res 1998;59:750-755.
15. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999;19:1252-1260.
16. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999;47:637-643.
17. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 1996; 124:717-725.
18. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-932.
19. Belfayol L, Talon P, Eveillard M, et al. Pharmacokinetics of once-daily amikacin in pediatric patients. Clin Microbiol Infect 1996; 2:186-191.
20. Bass KD, Larkin SE, Paap C, et al. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 1998; 33:1104-1107.
21. Agarwal G, Rastogi A, Pyati S. Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants ≥ 2500 g. J Perinatol 2002;22:268-274.
22. Godber LM, Walker RD, Stein GE, et al. Pharmacokinetics, nephrotoxicosis, and in vitro antibacterial activity associated with single versus multiple (three times) daily gentamicin treatments in horses. Am J Vet Res 1995;56:613-618.
23. Magdesian KG, Hogan PM, Cohen ND, et al. Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses. J Am Vet Med Assoc 1998; 213:1007-1011.
24. Easter JL, Hague BA, Brumbaugh GW, et al. Effects of post-operative peritoneal lavage on pharmacokinetics of gentamicin in horses after celiotomy. Am J Vet Res 1997;58:1166-1170.
25. Golenz MR, Wilson WD, Carlson GP, et al. Effect of route of administration and age on the pharmacokinetics of amikacin administered by the intravenous and intraosseous routes to 3- and 5-day-old foals. Equine Vet J 1994;26:367-373.
26. Green SL, Conlon PD, Mama K, et al. Effects of hypoxia and azotaemia on the pharmacokinetics of amikacin in neonatal foals. Equine Vet J 1992;24:475-479.
27. Wichtel MG, Breuhaus BA, Aucoin D. Relation between pharmacokinetics of amikacin sulfate and sepsis score in clinically normal and hospitalized neonatal foals. J Am Vet Med Assoc 1992; 200:1339-1343.
28. Brown MP, Gronwall RR, Martinez DS, et al. Pharmacokinetics of amikacin in pony foals after a single intramuscular injection. Am J Vet Res 1986;47:453-454.
29. Cummings LE, Guthrie AJ, Harkins JD, et al. Pharmacokinetics of gentamicin in newborn to 30-day-old foals. Am J Vet Res 1990;51:1988-1992.
30. Adamson PJ, Wilson WD, Hirsh DC, et al. Susceptibility of equine bacterial isolates to antimicrobial agents. Am J Vet Res 1985; 46:447-450.
31. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-1060.
32. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-27.
33. Orsini JA, Soma LR, Rourke JE, et al. Pharmacokinetics of amikacin in the horse following intravenous and intramuscular administration. J Vet Pharmacol Ther 1985;8:194-201.
34. Green SL, Conlon PD. Clinical pharmacokinetics of amikacin in hypoxic premature foals. Equine Vet J 1993;25:276-280.
35. Adland-Davenport P, Brown MP, Robinson JD, et al. Pharmacokinetics of amikacin in critically ill neonatal foals treated for presumed or confirmed sepsis. Equine Vet J 1990;22:18-22.
36. Langhendries JP, Battisti O, Bertrand JM, et al. Once-a-day administration of amikacin in neonates: Assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993;20:220-230.
37. Lundergan FS, Glasscock GF, Kim EH, et al. Once-daily gentamicin dosing in newborn infants. Pediatrics 1999;103:1228-1234.
38. Fisman DN, Kaye KM. Once-daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am 2000;14:475-487.
39. Mogg TD. Therapeutic monitoring in equine medicine, in Proceedings. 18th Annu Forum Am Coll Vet Intern Med 2000; 195-197.
40. Plumb DC. Amikacin sulfate. In: Plumb DC, ed. Veterinary drug handbook. 3rd ed. Ames, Iowa: Iowa State University Press, 1999; 17-21.